Hank F. Kung, Ph.D., Chief Scientific Advisor, Chairman of the Scientific Advisory Board.
Dr. Kung is a Professor of Radiology and Pharmacology at the University of Pennsylvania. He is regarded as a world leader in research and development of innovative radiopharmaceuticals for diagnosis of brain diseases including Alzheimer's disease and Parkinson's disease. Dr. Kung is the inventor of the radiopharmaceuticals IBZM (marketed in Europe) and Trodat (in clinical development in the U.S.) for Parkinson's disease. He has received numerous professional awards, including the Image-Of-The-Year award from American Society of Nuclear Medicine (1996 and 2002) for radiopharmaceuticals used in Parkinson's disease and the Springer award (European Journal of Nuclear Medicine) in 1997. Professor Kung recently received the Paul Aebersold award from the Society of Nuclear Medicine, the most prestigious honor for radiopharmaceutical chemists, in recognition for inventing radiopharmaceuticals for diagnosis of neurodegenerative disease.

Michael Devous, Ph.D. Expert in Brain Imaging and Regulatory Affairs.
Dr. Devous is currently a Professor of Radiology at the University of Texas Southwestern. He is the former President of the Society of Nuclear Medicine and former Chair of the Medical Imaging Drugs Advisory Committee for the FDA. Dr. Devous is the recipient of the 2004 Kuhl-Lassen Award, from the Brain Imaging Council awarded in recognition for Dr. Devous' wide-ranging investigations on the role of functional brain imaging in exploring the biology of psychiatric and neurological disorders. His work with functional brain imaging has impacted a multitude of areas including dementia and psychiatric disorders.

Joanna Fowler, Ph.D. Leading Researcher in PET Brain Imaging.
Dr. Fowler is a senior chemist and director of the PET program at Brookhaven National Laboratory and the Brookhaven Center for Translational Neuroimaging. Dr. Fowler has been a major contributor to brain research using PET. In 1976, Dr. Fowler and her colleagues synthesized 18F-fluorodeoxyglucose (FDG), the most commonly used PET radiotracer today (more than 1 million scans done in 2004). Dr. Fowler's work has garnered numerous honors, including the Jacob Javits Investigator Award in Neurosciences in both 1986 and 1993, The Gustavus John Esselen Award for Chemistry in the Public Interest, given by the Northeastern Section of the American Chemical Society (1988), the Aebersold Award from the Society of Nuclear Medicine (1997), the U.S. Department of Energy's E.O. Lawrence Award and the Francis P. Garvan-John M. Olin Medal, sponsored by the Olin Corporation Charitable Trust and administered by the American Chemical Society (1998), and, in 2002, she was awarded the Glenn T. Seaborg Award from the American Chemical Society. Dr. Fowler holds eight patents for radiolabeling procedures. Dr. Fowler is a member of the National Academy of Sciences.

Michael Kilbourn, Ph.D., Neuropharmacology Research Expert.
Dr. Kilbourn is a Professor of Radiology and Senior Research Scientist and Director of PET Chemistry at the University of Michigan. Dr. Kilbourn has more than twenty-five years experience in nuclear medicine, radiochemistry and radiopharmacology research. Dr. Kilbourn has conducted numerous research studies in the field of pharmacology utilizing radiolabeled ligands to study the molecular basis of psychiatric diseases. He has published over 100 research articles on the pharmacology of neuroreceptors, neurotransmitters and transporters involved in dementias, psychiatric disorders and drugs of abuse. Dr. Kilbourn is a co-inventor of 11C-DTBZ and 18F-FP-DTBZ; two important radiotracers for PET imaging of the vesicular monoamine transporter (VMAT-2), which is involved in a variety of dopaminergic diseases, such as Parkinson's disease, dementia with Lewy Bodies, Huntington's disease, Tourette's syndrome and attention-deficit hyperactivity disorder.

James Smith, Ph.D. Expert in Radiopharmaceutical Development.
Dr. Smith has over twenty years of experience in the pharmaceutical industry. He formerly served as Executive Vice-President of Research and Development at EPIX Medical Inc. Prior to joining EPIX, Dr. Smith served as Senior Director of Radiopharmaceutical Research and Development at DuPont Pharmaceutical Company, where he directed development of Cardiolite®, the world's top-selling radiopharmaceutical (2005 sales in excess of $400 million).

Henry Wagner, Jr., M.D. Pioneer in Nuclear Medicine.
Dr. Wagner is the founder of Johns Hopkins University PET Center and currently practices there as the Director of the Division of Radiation Health Sciences, Professor Emeritus of Radiology and Radiological Science, Professor Emeritus of Medicine, Principal Professor at the Applied Physics Laboratory and Professor of Environmental Health Sciences. Dr. Wagner is a past president of the Society of Nuclear Medicine (SNM, a 15,000 member professional organization for nuclear medicine physicians and scientists). Dr. Wagner is the co-author of more than 800 publications, and was the first scientist to image the kidneys with radiomercury labeled chlormerodrin (1960), image lung perfusion and ventilation (for pulmonary embolism) (1968) and image neuroreceptors using a PET radiotracer (1983). Dr. Wagner is the recipient of numerous awards and honors, including: SNM's President's Award for Outstanding Contributions to Nuclear Medicine, the Georg Von Hevesy Award from SNM, and three honorary degrees. He is a world renowned thought leader, and is a member of the Institute on Medicine, the National Academy of Sciences, the NIH Advisory Board for PET and the FDA panel for Radiology Devices. In addition Dr. Wagner is an advisory expert for the WHO, and is the National Nuclear Medicine Consultant to the Surgeon General of the United States.